• IMRT is now an accepted standard for LA NSCLC radiotherapy • Specific dose-constraints on low doses should be adopted • Ongoing trials will clarify us the role of PET-guided hypo- fractionated boost and the best chemotherapy combination • New drugs will hopefully amplify the benefit of the combined modality approach

Made with